KarinCA Sunday, 12/23/12 12:54:34 PM Re: Gratefullife post# 15360 Post # of 146260 Cellceutix has stated several times that there isn't competition to their drug kevetrin. Several companies have been working on it, but, none have achieved the same results. Kevetrin works on both the mutated and wild type p53. The competition seems to only work on the wild form. Kevetrin will end up working on many more cancers since it works on the mutated form. Kevetrin is an HDAC-2 and HDAC-6 regulators. HDM2 is an inhibitor. Kevetrin has several other subordinate activities, such as, regulating c-myc activity, inducing apoptosis, etc.. It has also been seen that Kevetrin has anti-angiogenic properties. See my earlier post including info from company: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82597857 See progressive post of earlier PR dealing with this: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82732988 Also, see search of FDA website for the other companies trials and you will notice HDM2 isn't listed yet. http://www.clinicaltrial.gov/ct2/results?term=Ascenta+Therapeutics%2C+Inc&Search=Search KarinCAtrades.com GLTA... KarinCA ;) "Be kinder than necessary, for everyone you meet is fighting some kind of battle."